Castleman disease
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Multicentric Castleman’s disease
Siltuximab (Sylvant)
Regimen #1, Wong et al. 2013
Phase II
Patients in Wong et al. 2013 had symptomatic, measurable, HIV-negative, and HHV-8-negative multicentric Castleman’s disease (MCD).
- Siltuximab (Sylvant) 11 mg/kg IV over 1 hour once on day 1
21-day cycles, given until treatment failure
Regimen #2, Kurzrock et al. 2013
Phase I
This dose was the recommended dose after the dose-finding study Kurzrock et al. 2013. Note that this is different from the FDA-approved dose, which is 11 mg/kg.
- Siltuximab (Sylvant) 12 mg/kg IV over 1 hour once on day 1
21-day cycles, given until progression of disease or unacceptable toxicity
References
- Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 1;19(13):3659-70. link to original article contains verified protocol PubMed
- Abstract: Raymond S Wong, Corey Casper, Nikhil Munshi, Xiaoyan Ke, Alexander Fosså, David Simpson, Marcelo Capra, Ting Liu, Ruey Kuen Hsieh, Yeow Tee Goh, Jun Zhu, Seok-Goo Cho, Hanyun Ren, James Cavet, Rajesh Bandekar, Margaret Rothman, Thomas A Puchalski, Shalini Chaturvedi, Helgi van de Velde, Jessica Vermeulen, and Frits van Rhee. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease. 2013 ASH Annual Meeting abstract 505. link to abstract